Director, First Department of Thoracic Oncology, Chief Physician / Professor. Specializes in thoracic tumors, particularly in the clinical diagnosis, treatment and research of lung cancer, pleural mesothelioma and thymic tumors, and has established systematic working approaches and frameworks. Focuses on the MDT diagnosis‑and‑treatment model and devotes to individualized comprehensive therapy, with special attention to elderly lung cancer. Balancing treatment safety and survival benefits, he develops individualized regimens for elderly patients. His translational research centers on the tumor microenvironment. He innovatively proposed the "microbe‑tumor metabolic coupling" theory, and systematically elucidated the mechanism by which lung adenocarcinoma‑associated microbiota activates the HIF‑1α pathway via the lactate‑MCT1 axis, offering new insights for microenvironment‑targeted therapy. As a member of the expert panel for the CSCO Guidelines for the Diagnosis and Treatment of Non‑Small‑Cell Lung Cancer and associate editor‑in‑chief of the CACA Guidelines for the Protection of Elderly Patients with Lung Cancer, he has participated in formulating multiple industry standards. He is the chief editor of Comprehensive Therapeutics of Elderly Lung Cancer, which has become a key reference book in this field.

Publications: ‑ Lactate production by tumor‑resident Staphylococcus promotes metastatic colonization in lung adenocarcinoma. Cell Host & Microbe. 2025; 33, 1089–1105. ‑ Prognostic significance of micropapillary pattern and risk factors in patients with resected stage I lung adenocarcinoma and possible benefit of adjuvant therapy: a real‑world multicenter study. Transl Lung Cancer Res 2025; 14(7):2760‑2770 ‑ Secreted proteins MDK, WFDC2, and CXCL14 as candidate biomarkers for early diagnosis of lung adenocarcinoma. BMC Cancer. 2023; 23:110 ‑ Significant Upregulation of HERV‑K (HML‑2) Transcription Levels in Human Lung Cancer and Cancer Cells. Frontiers in Microbiology. March 2022 | Volume 13 | Article 850444 ‑ Identification of serum biomarkers to predict pemetrexed/platinum chemotherapy efficacy for advanced lung adenocarcinoma patients by data‑independent acquisition (DIA) mass spectrometry analysis with parallel reaction monitoring (PRM) verification. Transl Lung Cancer Res 2021;10(2):981‑994